HC Wainwright Weighs in on Cibus’ Q2 Earnings (NASDAQ:CBUS)

Cibus, Inc. (NASDAQ:CBUS) – Stock analysts at HC Wainwright cut their Q2 2026 EPS estimates for shares of Cibus in a research note issued to investors on Friday, May 15th. HC Wainwright analyst A. Dayal now forecasts that the company will post earnings per share of ($0.26) for the quarter, down from their prior forecast of ($0.24). The consensus estimate for Cibus’ current full-year earnings is ($1.26) per share. HC Wainwright also issued estimates for Cibus’ Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.05) EPS, FY2027 earnings at ($1.06) EPS, FY2028 earnings at ($0.49) EPS and FY2029 earnings at $0.28 EPS.

A number of other equities analysts also recently issued reports on CBUS. Jefferies Financial Group raised their price objective on shares of Cibus from $1.90 to $3.00 and gave the stock a “hold” rating in a report on Wednesday, March 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a report on Wednesday, January 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $9.00.

Cibus Stock Down 2.3%

Shares of NASDAQ CBUS opened at $1.28 on Tuesday. The firm’s 50-day moving average price is $2.04 and its 200-day moving average price is $1.97. The company has a market cap of $97.70 million, a PE ratio of -0.65 and a beta of 1.66. Cibus has a 52-week low of $1.09 and a 52-week high of $4.19.

Cibus (NASDAQ:CBUS) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($0.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). The company had revenue of $1.68 million for the quarter, compared to analysts’ expectations of $1.61 million. Cibus had a negative net margin of 2,366.33% and a negative return on equity of 200.87%.

Hedge Funds Weigh In On Cibus

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Certior Financial Group LLC boosted its holdings in shares of Cibus by 6.5% in the third quarter. Certior Financial Group LLC now owns 184,786 shares of the company’s stock worth $238,000 after buying an additional 11,230 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of Cibus by 4.7% in the fourth quarter. Geode Capital Management LLC now owns 275,180 shares of the company’s stock worth $479,000 after buying an additional 12,467 shares during the last quarter. Raymond James Financial Inc. boosted its holdings in shares of Cibus by 31.0% in the second quarter. Raymond James Financial Inc. now owns 53,713 shares of the company’s stock worth $74,000 after buying an additional 12,722 shares during the last quarter. PACK Private Wealth LLC purchased a new position in shares of Cibus in the fourth quarter worth approximately $27,000. Finally, Dimensional Fund Advisors LP purchased a new position in shares of Cibus in the first quarter worth approximately $33,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

More Cibus News

Here are the key news stories impacting Cibus this week:

• Positive Sentiment: Sidoti raised earnings estimates for several upcoming quarters, including Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027, suggesting a modestly better outlook for Cibus’ loss trajectory. Cibus analyst estimate update
• Positive Sentiment: Sidoti also improved its FY2027 EPS forecast for Cibus, indicating analysts see some longer-term improvement in profitability. Cibus FY2027 estimate update
• Neutral Sentiment: HC Wainwright slightly adjusted some longer-range estimates, with mixed changes across FY2026, FY2027, FY2028, and FY2029, which does not materially change the near-term investment case. Cibus HC Wainwright estimate update
• Negative Sentiment: Despite the analyst revisions, Cibus is still expected to post significant losses in the coming years, with full-year 2026 EPS consensus at -$1.26 and FY2027 still projected to be negative at about -$1.02, reinforcing concerns about profitability. Cibus profitability outlook

Cibus Company Profile

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.